Venous stenting was introduced in the 1990s and has continued to evolve to become the first-line therapy for symptomatic iliofemoral venous outflow pathology. There are several dedicated venous stents available in addition to Boston Scientific’s Wallstent and Cook’s Z-Stent. Numerous studies from tertiary referral centres, as well as industry-sponsored trials, have demonstrated the safety and efficacy of these endovascular devices for non-thrombotic iliocaval vein (NIVL) and post-thrombotic syndrome (PTS) lesions. Patients presenting with acute deep venous thrombosis (aDVT) may also undergo stenting following thrombus removal. The standard of care for NIVL, PTS and aDVT patients has become venography and intravascular ultrasound, and if an underlying iliofemoral stenosis is identified, a stent is placed. There is a concern that inflammation may affect the results of stenting in the aDVT population. Although endovascular stenting for acute venous diseases appears promising and safe, there is a paucity of data on efficacy in aDVT patients. There are only two industry-sponsored trials and a few publications and presentations at academic society meetings to examine. This review assesses the available results for endovascular stenting for aDVT and PTS patients, but not for NIVL.

**Keywords**

Stent, venous, deep venous thrombosis, iliocaval, femoral, iliac

**Disclosure**: PM is on the advisory board for Medtronic and Boston Scientific, and has received payment for lectures at Penumbra and BD. All other authors have no conflicts of interest to declare.

**Acknowledgements**: The authors thank Hatton Research Institute, TriHealth Inc. (Cincinnati, OH, US) for research support and guidance.

**Received**: 18 June 2022 **Accepted**: 23 November 2022 **Citation**: Vascular & Endovascular Review 2023;6:e03. **DOI**: https://doi.org/10.15420/ver.2022.07

**Correspondence**: Patrick Muck, Division of Vascular Surgery, TriHealth – Good Samaritan Hospital, 375 Dixmyth Ave, Cincinnati, OH 45220, US. E: Patrick_Muck@Trihealth.com

**Open Access**: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Acute venous disease affects tens of millions of people globally. Acute venous pathologies include superficial venous thrombophlebitis, acute deep venous thrombosis (aDVT) and pulmonary embolism. Lower limb venous thromboembolism (VTE) is quite common, with an incidence ranging from 88 to 112 per 100,000 person-years. Lower limb VTE is also associated with a high morbidity and mortality. In addition, the incidence of recurrent deep venous thrombosis (DVT) ranges from 20% to 36% within 10 years from the initial event. The first-line therapy acute DVT (aDVT) is anticoagulation therapy. Strategies to facilitate thrombus reduction may decrease the risk of post-thrombotic syndrome (PTS) or recurrent venous thromboembolism. The therapeutic options include catheter-directed thrombolysis, rheolytic thrombectomy, aspiration thrombectomy or mechanical thrombectomy. Intravascular ultrasound (IVUS) following thrombus removal dissolution has become the standard of care to assess for iliofemoral venous stenoses, which are frequently discovered; in these cases, endovascular stents are placed to alleviate the obstructive lesion. There are limited data on the efficacy of stenting in this clinical scenario.

Chronic venous disease can be due to deep, superficial or perforator venous insufficiency, including obstruction, stenosis or valvular reflux. Deep venous disease can be secondary agenesis, stenosis, obstruction or reflux. Venous stenosis and obstruction can be due to aDVT, PTS or non-thrombotic iliocaval vein lesions (NIVL) and/or reflux due to valvular insufficiency. A high percentage of limbs with iliocaval vein obstruction will also have reflux below the inguinal ligament, resulting in peripheral venous hypertension. These pathologies cause chronic venous hypertension, resulting in inflammatory changes to peripheral tissues. Clinically, this causes limb pain, oedema, lipodermatosclerotic changes and venous leg ulcerations. Over 25 million people worldwide are affected by deep venous obstruction. Symptomatic iliofemoral outflow obstruction is a substantial contributor to chronic venous insufficiency and is increasingly being treated through an endovascular approach.

Venous stenting was introduced in the 1990s and has continued to evolve as a viable option for iliac venous pathology. Although endovascular treatment for venous diseases appears promising and safe, there is a need to improve our knowledge of optimal venous stent strategies. There are several dedicated venous stents available, in addition to Boston Scientific’s WALLSTENT and Cook’s Z-Stent (Table 1), for symptomatic iliofemoral outflow obstruction. These devices perform well for NIVL and PTS. Although endovascular stenting for acute venous diseases appears promising and
safe, there is a paucity of data on efficacy in aDVT patients, with only two industry-sponsored trials and a few publications and presentations at academic society meetings to examine. Unfortunately, not every paper or academic society presentation used the same definitions of aDVT or PTS. In this review, we define aDVT as ≤4 weeks in duration and PTS as >4 weeks in duration. This review assesses the available results for endovascular stenting for aDVT and PTS patients, but not for NIVL.

### Venous Pathophysiology

Three major types of iliacaval venous obstruction are recognised: NIVL, aDVT and PTS iliac vein stenosis. NIVL vessels tend to harbour focal short lesions secondary to compression by an adjacent artery, other extrinsic lesions or the inguinal ligament. Cockett et al. originally described the first NIVL in 1900, and the term ‘May–Thurner syndrome’ was later used.

Today, a diverse spectrum of non-thrombotic iliac vein lesions are identified using venograms and IVUS. These imaging techniques have confirmed that iliac vein compression posterior to the crossing right common iliac artery is present in as many as two-thirds of the general population. Increased use of IVUS has shown venous stenoses to be present at more diverse locations in the pelvic venous anatomy and that it affects a much broader demographic than the narrow band recognised by Cockett et al. The Venogram versus IVUS for Diagnosing Iliac vein Obstruction (VIDIO) trial concluded that IVUS was more sensitive and specific in detecting venous stenoses >50\% than multiplanar venography. The available data suggest NIVLs to be focal lesions.

Post-thrombotic syndrome is the lifelong sequela of a DVT. The result is pain, swelling and skin changes in up to 50\% of patients treated with anticoagulation alone. In the acute phase, the vessel has a thrombus with mild surrounding vessel wall inflammation. Research has shown that a vein undergoes a fibrotic process secondary to intense inflammation following DVT. Studies have also shown that the vein may undergo thickening as it responds to thrombus resolution with inflammation and increased biomarkers. As a result, blood flow and haemodynamics will be negatively altered. In its most severe form, the vein will end up with a long-segment chronic occlusion. These fibrotic changes are considered the reason for decreased patency following venous stenting for PT lesions as opposed to NIVLs.

Today, many devices have proven effective in treating patients with acute DVT. IVUS is recommended following thrombus removal to identify underlying iliofemoral venous outflow obstruction. Currently, there are limited data on the venous pathophysiology following thrombus removal. Inflammation likely occurs secondary to the venous thrombus, but there is no consensus on the short- and long-term effects. Research is needed to determine whether the aDVT vein reacts like an NIVL or PTS following thrombolyis or thrombectomy. There are also limited data on the long-term effects of endovascular stenting following thrombus removal for aDVT. Furthermore, the role of anticoagulation and inflammation management is not well studied either. Most key opinion leaders believe full anticoagulation is needed in this scenario of inflammation and thrombogenicity.

In a recent presentation at the 34th Annual Meeting of the American Venous Forum, Marston concluded that treatment with low molecular weight heparin (LMWH) should transition to a direct oral anticoagulant (DOAC) at 4 weeks. The data presented indicated better patency with LMWH in these acute thrombotic situations compared with DOACs.

### Indications for Stenting

Chronic venous disease, in general, is a non-lethal disease and the loss of a limb is a rarity. If symptoms resulting from iliacaval or iliofemoral stenoses are present, conservative treatment with compression is the initial treatment modality. This modality will fail in ≥50\% patients because of inefficacy or, more often, non-compliance with compression regimens. Iliac vein stenting may be carefully considered after failure of conservative treatment. Patients are categorised based on the Clinical–Etiology–Anatomy–Pathophysiology (CEAP) system. In general, only patients with CEAP classes 3–6 are candidates for the correction of underlying venous lesions. A recent randomised study compared outcomes of medical treatment versus iliac vein stenting in patients with chronic venous diseases and found significant reductions in pain and the Venous Clinical Severity Score (VCSS), along with a significant improvement in quality of life following endovascular treatment. Despite a lack of prospective randomised trials for venous stenting patient populations, both the American Venous Forum/Society of Vascular Surgery and European Society of Vascular Surgery have guidelines on the management of chronic venous disease.

Currently, percutaneous transluminal angioplasty and stenting are recommended as first-line treatments in patients with symptomatic iliofemoral venous outflow obstruction.

### Endovascular Stenting Technique

Arterial and venous haemodynamics differ. Perhaps the only analogy between arterial and venous stenting is the common vascular principles of inflow, outflow and conduit. A well-thought-out plan beginning with preprocedural imaging is a necessity. CT venography and duplex imaging are the most commonly used modalities. Popliteal, high posterior tibial, mid-thigh ipsilateral femoral vein or internal jugular vein access under ultrasound guidance is preferred. A large sheath, typically 8–10 Fr, is preferred for easy manipulation of inserted devices, larger if a Z-Stent is used. These approaches allow enough room for the sheath to deploy stents below the inguinal ligament if needed. IVUS examinations of the inferior vena cava (IVC), common iliac vein, external iliac vein, common femoral vein and profunda femoral vein are conducted to identify lesions and appropriate landing sites. IVUS is used to measure diameters and areas. The degree of stenosis is best calculated using the expected normal area for the location. Using the ipsilateral adjacent normal lumen as a reference is the method used the most. Most symptomatic limbs will have ≥50\% area reduction, although some lesser lesions can be symptomatic in individual patients with PTS due to severe compliance changes. Recently Gagne et al. showed that a 61\% reduction in diameter, not area, is correlated with symptom relief after stenting.

Treating the entire diseased segment or lesion in continuity with landing sites clear of disease is essential for successful outcomes. The principles of inflow, outflow and conduit apply in venous therapies. A high-pressure

---

**Table 1: Currently Available Venous Stents**

<table>
<thead>
<tr>
<th>Device</th>
<th>Design</th>
<th>Cell Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>WALLSTENT (Boston Scientific)</td>
<td>Steel</td>
<td>Closed</td>
</tr>
<tr>
<td>Venovo (BD)</td>
<td>Nitinol</td>
<td>Open</td>
</tr>
<tr>
<td>Zilver Vena (Cook Medical)</td>
<td>Nitinol</td>
<td>Open</td>
</tr>
<tr>
<td>Abre (Medtronic)</td>
<td>Nitinol</td>
<td>Open</td>
</tr>
<tr>
<td>sinus-Venous (Optmed)</td>
<td>Nitinol</td>
<td>Open</td>
</tr>
<tr>
<td>sinus-Obliquus (Optmed)</td>
<td>Nitinol</td>
<td>Hybrid</td>
</tr>
<tr>
<td>Z-stent (Cook Medical)</td>
<td>Steel</td>
<td>Open</td>
</tr>
<tr>
<td>blueflow Venous Stent (plus medica)</td>
<td>Nitinol</td>
<td>Closed</td>
</tr>
</tbody>
</table>
Acute versus Chronic Iliocaval DVT: Difference When Stenting

In another review, remarkable and highlights the WALLSTENT’s decades of use, showing its success and durability in terms of both patency and clinical outcomes. Because the WALLSTENT is a closed-cell stent, there is a concern it can impede flow from the contralateral iliac leading to contralateral iliac DVT. Successful treatment of an occluded IVC filter with two WALLSTENTS is shown in Figure 1.

Available Venous Stents and Data on Patients with Acute Deep Venous Thrombosis and Post-thrombotic Syndrome

The WALLSTENT endoprosthesis from Boston Scientific has been the workhorse for venous stenting for several decades. Raju and Neglén’s early work is remarkable and highlights the WALLSTENT’s decades of benefit for patients with venous occlusive disease. The WALLSTENT is a closed-cell woven stent with a wide variety of lengths and diameters. The WALLSTENT has very good crush resistance and radial force, and performs quite well through the pelvic tortuosity because of its good flexibility. The WALLSTENT has very good crush resistance and radial force, and performs quite well through the pelvic tortuosity because of its good flexibility. The WALLSTENT has very good crush resistance and radial force, and performs quite well through the pelvic tortuosity because of its good flexibility. The WALLSTENT has very good crush resistance and radial force, and performs quite well through the pelvic tortuosity because of its good flexibility. The WALLSTENT has very good crush resistance and radial force, and performs quite well through the pelvic tortuosity because of its good flexibility.

WALLSTENT placement with displacement of the IVC filter laterally.

Figure 1: WALLSTENT Placement Following Thrombectomy of Acute Inferior Vena Cava Filter Occlusion
A. Occluded Inferior Vena Cava Filter treated with aspiration thrombectomy. B. Double barrel WALLSTENT placement with displacement of the IVC filter laterally.

Figure 2: Venovo Placement Following Thrombectomy of Acute Iliofemoral Deep Venous Thrombosis
A. Venogram after aspiration thrombectomy of iliofemoral deep vein thrombosis. B. Treatment of underlying common iliac vein lesion with Venovo stent.

with catheter-directed thrombolysis (with or without thrombectomy), followed by percutaneous transluminal angioplasty and stent placement, with the WALLSTENT used in 78% of included studies. In another review, Husmann et al. included 11 patients treated with thrombolysis/thrombectomy followed by iliac venous WALLSTENT placement. These are examples of the literature supporting the efficacy of Boston Scientific’s WALLSTENT in treating patients after dDVT dissolution or extraction.

Venovo
BD’s Venovo is an open-cell, self-expanding nitinol stent that comes in various sizes. The Venovo was the first stent with a venous indication approved by the Food and Drug Administration (in March 2019). The VERNACULAR Trial is a prospective single-arm multicentre worldwide study that has included 200 subjects with symptomatic iliofemoral venous outflow obstruction from sites throughout the US and Europe. The Venovo stent met its primary endpoint with excellent 36-month patency. The placement of Venovo stents following an iliofemoral venous thrombectomy is shown in Figure 2.

The 3-year results of the VERNACULAR trial were recently presented by Dake et al. The Venovo venous stent was successfully deployed in obstructive iliofemoral vein lesions and met the pre-specified primary outcome measures through 12 months. At 3 years, primary patency was 84%, reintervention rates were low, standardised quality of life and pain measures improved from baseline and there was no stent migration or fractures. However, the VERNACULAR trial did not enrol patients with aDVT.

Abre
Medtronic’s Abre is an open-cell nitinol stent that comes in various sizes. The ABRE Study was a prospective interventional single-arm multicentre worldwide study that included 200 subjects with symptomatic iliofemoral venous outflow obstruction from 24 sites throughout the US and Europe. The study enrolled subjects across the spectrum of deep venous disease, including those with PTS (47%) and NIVL (36%), as well as those who presented with an aDVT (17%). The study also met its 12-month primary effectiveness endpoint, with an overall primary patency rate of 82.8% (162/184). Furthermore, the data demonstrated a freedom from clinically driven target lesion revascularisation rate of 92.4% (170/184) through 390 days.

Notable secondary endpoint results from the ABRE Study included no stent fractures and no delayed stent migration observed within 12
Results.

These positive data signal a benefit to treating patients with the Zilver Vena dedicated venous stent following thrombus dissolution/extraction when IVUS confirms an iliofemoral lesion. Successful Abre stent placement following thrombus removal is shown in Figure 3.

Zilver Vena

The Zilver Vena is an open-cell, self-expanding nitinol stent that obtained a CE Mark in 2010. Cook Medical has completed the VIVO clinical trial evaluating the effectiveness of the Zilver Vena for iliofemoral occlusive disease.20,21 VIVO was a prospective single-arm multicentre worldwide study that included 243 subjects with symptomatic iliofemoral venous outflow obstruction from 24 sites throughout the US and Europe. The study included a real-world population, encompassing subjects across the spectrum of deep venous disease, including those with PTS (43%) and NVL (33%), as well as those who presented with an aDVT (24%).22 Results though 2 years continue to support the safety and effectiveness of the Zilver Vena venous stent for the treatment of symptomatic iliofemoral venous outflow obstruction. In addition, the study revealed high rates of freedom from clinically driven reintervention, high rates of patency by ultrasound, clinical improvement (as measured by the VCSS) and no stent fractures.

The Zilver Vena was demonstrated to have high patency by ultrasound at 2 years. In the aDVT groups, patency was 84% at 2 years, whereas in the chronic DVT (PTS) group patency was 86.1% at 2 years.23 Freedom from major adverse events was similar between the groups at 94.9% and 95.1% in the aDVT and chronic DVT (PTS) groups, respectively.23 There was a significant improvement in the mean VCSS from baseline (p<0.0001) in the VIVO study cohort at 1 month, and this improvement was maintained through 2 years. The mean VCSS decreased by 4.2 points from before the procedure through to 2 years. Subgroup analysis demonstrated the same trend for clinical improvement in each subgroup.23 These positive data signal a benefit of treating patients with the Zilver Vena dedicated venous stent following thrombus dissolution/extraction. Successful placement of a Zilver Vena on the iliofemoral confluence after iliofemoral DVT thrombolysis is shown in Figure 4.

Blueflow Venous Stent

A novel braided nitinol stent (blueflow Venous Stent; plus medica) provides additional flexibility due to its braided structure and high radial force due to its closed cell design. The BLUEFLOW Registry evaluated the mid-term effectiveness and safety of iliofemoral venous recanalisation using a novel braided venous stent in participants with chronic venous disease.24 The study demonstrated favourable primary patency at 12 months without major complications. Symptom severity, as measured by the revised VCSS (rVCSS) and clinical CEAP score, improved significantly, with an advantage for obstructions of the external over the common iliac vein. No significant difference in effectiveness could be found between thrombotic and non-thrombotic pathogenesis. The results suggest that deep venous stenting with the blueflow Venous Stent provides favourable primary patency and is associated with significant sustained improvement of symptom severity in a real-world population with obstructive chronic venous disease up to 12 months. This adds to the number of dedicated venous stents available for chronic DVT patients. Additional research is needed for aDVT patients.26

Z-stent

Stenting of the proximal iliofemoral confluence deserves special consideration. Incomplete stent coverage in this area is a common cause of residual symptoms. IVUS coupled with bony landmarks as fluoroscopic markers is mandatory for accurate treatment. Extension of the iliac stent for a few centimetres into the IVC is generally required to traverse the proximal lesion in its entirety when using Boston Scientific’s WALLSTENT. An 18- or 20-mm stent dilated with 16- and 18-mm balloons, respectively, will accommodate most adults and provide a 2 mm reserve for extra dilation later, if required. Alternatively, a Z-stent (Cook) may be used proximally (within the WALLSTENT) for added radial strength under the artery and to minimise jailing of the contralateral iliac outflow.25 A significant reduction in contralateral DVT has been observed with the Z-stent extension compared with the WALLSTENT extension. The Z-stent has safety and efficacy in PTS patients, but additional research is needed for aDVT patients.

Single-institution Data on Venous Stenting for Patients With Acute Deep Venous Thrombosis and Post-thrombotic Syndrome

A few non-industry studies have examined differences in patency in patients with aDVT following thrombus removal and PTS stenoses. The recently published paper Venous Stent Patency is Independent of Total Stented Length in Non-thrombotic Iliac Vein and Post-thrombotic Venous Stenoses...
Of these 53 patients, 34 (64%) were classified as acute DVT versus chronic DVT or thrombotic versus non-thrombotic. A total stented length was not predictive of loss of patency. In that study, the majority of stents used were Wallstent, Venovo and Abre, which supports their use in patients with aDVT and PTS.

In another paper, published by Tran et al. from the Heart and Vascular Institute, University of Pittsburgh Medical Center (Pittsburgh, PA, US), in 150 patients undergoing iliocaval stenting for deep venous disease, adjunct IVUS assessment with multiplanar venography was associated with higher 30-day (98.6% versus 89.4%; p=0.02) and 2-year (90.3% versus 78.7%; p=0.03) primary patency than venography alone. In this study, 55.3% acute, 1.3% chronic or post-thrombotic and 23.3% of patients underwent intervention for NIVLs, with IVUS and venography-guided stenting compared between the groups. The patency of the stent group with aDVT was 88% compared with 86% in the post-thrombotic stenosis group, which was not statistically different. These data signal a benefit to stenting at the time of aDVT thrombectomy or thrombolysis. Tran et al. used a mixture of stents (61% and 47% Wallstent in the aDVT and chronic disease patients, respectively). Importantly, the type of venous disease (i.e. aDVT versus chronic DVT or thrombotic versus non-thrombotic) was not found to be a risk factor for 30-day or 2-year stent failure in univariate or multivariate regression analyses. Lichtenberg et al. published data from the Arnsberg Aspirex Registry, including 56 patients with iliofemoral DVT. Patients were examined for acute and subacute DVTs, with 40 (71%) being acute. All patients underwent placement with dedicated venous stents following treatment with Aspirex. The cumulative patency after 1, 5 and 12 months was 95%, 94% and 87%, respectively. Clinical variables were also collected assessing for PTS. PTS analysis after 12 months was reported for 53 patients. Of these 53 patients, 34 (64%) were classified as low PTS (CEAP score <3, rVCSS <3), whereas 19 (36%) had moderate PTS (CEAP score >3, rVCSS >3). These compelling data support endovascular stent placement in aDVT patients following thrombus dissolution/extraction, as well as in PTS patients.

Conclusion

Raju and Neglén pioneered venous stenting, demonstrating its safety and efficacy for symptomatic iliofemoral outflow obstruction. Boston Scientific’s Wallstent has been the most frequently studied device for venous stenting in NIVL, aDVT and PTS patients. Data for patients with aDVT are accumulating for dedicated venous stents. Today, there is promising data accumulating from industry trials and non-industry-sponsored research. Medtronic’s and Cook’s industry-sponsored trials show the benefits of Abre and Zilver Vena, respectively, for stenting in patients with aDVT. Independent research has also revealed positive long-term results with venous stenting for aDVT patients following thrombus removal. More research is needed to identify the best practice for patients with aDVT and the best comprehensive approach. Currently, data from industry trials and from institutions across the world signal the benefit of venous stenting for patients with aDVT following thrombus removal. Although more data are needed, currently the results appear similar whether a venous stent is placed following thrombus removal for aDVT or for PTS.


